Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test

European Journal of Pharmacology

Volumn 565, Issue 1-3, 2007, Pages 125-131

  Zeidan, Mariana P ^a   Zomkowski, Andréa D E ^a   Rosa, Angelo O ^a   Rodrigues, Ana Lúcia S ^a   Gabilan, Nelson H ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Agmatine; Antidepressant like effect; Forced swimming test; Imidazoline receptors

Indexed keywords

AGMATINE; ANTAZOLINE; CLONIDINE; DIZOCILPINE; EFAROXAN; IDAZOXAN; IMIDAZOLINE RECEPTOR; MOXONIDINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR BINDING;

AGMATINE; ANIMALS; ANTAZOLINE; ANTIDEPRESSIVE AGENTS; BENZOFURANS; CLONIDINE; FEMALE; IMIDAZOLES; MALE; MICE; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING;

EID: 34249328527     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.03.027     Document Type: Article

References (45)

1. Bousquet P., Feldman J., Tibirica E., Bricca G., Greney H., Dontenwill M., Stutzmann J., and Belcourt A. Imidazoline receptors. A new concept in central regulation of the arterial blood pressure. Am. J. Hypertens. 5 (1992) 47S-50S
2. Bousquet P., Bruban V., Schann S., and Feldman J. Imidazoline receptors: a challenge. Pharm. Acta Helv. 74 (2000) 205-209
3. Cervo L., Grignaschi G., and Samanin R. α2-Adrenoceptor blockade prevents the effect of desipramine in the forced swimming test. Eur. J. Pharmacol. 175 (1990) 301-307
4. Cervo L., Rossi C., and Samanin R. The role of serotonin and dopamine in brain in the antidepressant-like effect of clonidine in the forced swimming test. Neuropharmacology 31 (1992) 331-335
5. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., and Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19 (1998) 381-390
6. 1-imidazoline receptor and its cellular signaling pathways. Ann. N.Y. Acad. Sci. 881 (1999) 35-53
7. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 264 (1993) 172-182
8. Fairbanks C.A., and Wilcox G.L. Moxonidine, a selective α2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J. Pharmacol. Exp. Ther. 290 (1999) 403-412
9. Farsang C., and Kapocsi J. Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). Brain Res. Bull. 49 (1999) 317-331
10. 2 receptor selective ligand BU224 in naive rats and rat exposed to the stress of the forced swim test. Psychopharmacology 167 (2003) 195-202
11. 2 sites in the mammalian central nervous system. Pharmacol. Ther. 68 (1995) 175-208
12. Garcia-Sevilla J.A., Escriba P.V., Sastre M., Walter C., Busquets X., Jaquet G., Reis D.J., and Guimon J. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch. Gen. Psychiatry 53 (1996) 803-810
13. 1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. Br. J. Pharmacol. 114 (1995) 751-754
14. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
15. Lu G., Su R.B., Li J., and Qin B.Y. Modulation by alpha-difluoromethyl-ornithine and aminoguanidine of pain threshold, morphine analgesia and tolerance. Eur. J. Pharmacol. 478 (2003) 139-144
16. Martel J.C., Chopin P., Colpaert F., and Marlen M. Neuroprotective effects of the α2-adrenoceptor antagonist, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp. Neurol. 154 (1998) 595-601
17. Milhaud D., Fagni L., Bockaert J., and Lafon-Cazal M. Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacology 39 (2000) 2244-2254
18. Milhaud D., Rondouin G., Lerner-Natoli M., Bockaert J., and Lafon-Cazal M. Neuroprotective activity of antazoline against neuronal damage induced by limbic status epilepticus. Neuroscience 120 (2003) 475-484
19. Moinard C., Cynober L., and Bandt J.P. Polyamines: metabolism and implications in human diseases. Clin. Nutr. 24 (2005) 184-197
20. Molderings G.J. Imidazoline receptors: basic knowledge, recent advances and future prospects for therapy and diagnosis. Drugs Future 22 (1997) 757-772
21. Nemeroff C.B., and Owens M.J. Treatment of mood disorders. Nat. Neurosci. 5 (2002) 1068-1070
22. Nutt D.J., French N., Handley S.L., Hudson A., Husbands S., Jackson H., Jordan S., Lalies M.D., Lewis J., Lione L., et al. Functional studies of specific imidazoline-2 receptor ligands. Ann. N.Y. Acad. Sci. 763 (1995) 125-139
23. Onal A., and Soykan N. Agmatine produces antinociception in tonic pain in mice. Pharmacol. Biochem. Behav. 69 (2001) 93-97
24. 2 ligands do not show antidepresant-like activity in the forced swim test in mice. J. Psychopharmacol. 15 (2001) 18-22
25. Piletz J.E., Ernsberger P.R., and Halaris A. Psychopharmacology of imidazoline and α2-adrenergic receptors: implications for depression. CRC Crit. Rev. Neurobiol. 9 (1995) 29-66
26. 1-imidazoline binding sites are elevated in depression but not in generalized anxiety disorder. J. Psychiatr. Res. 30 (1996) 147-168
27. 1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 279 (1996) 694-702
28. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
29. Prow M.R., Martin K.F., and Heal D.J. 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation. Eur. J. Pharmacol. 317 (1996) 21-28
30. 2 specific ligands in vitro. Pharm. Pharmacol. Lett. 6 (1996) 42-45
31. Raasch W., Muhle H., and Dominiak P. Modulation of MAO activity by imidazoline and guanidine derivatives. Ann. N.Y. Acad. Sci. 881 (1999) 313-331
32. Raasch W., Schafer U., Chun J., and Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br. J. Pharmacol. 133 (2001) 755-780
33. Raghavan S.A.V., and Dikshit M. Vascular regulation by the l-arginine metabolites, nitric oxide and agmatine. Pharmacol. Res. 49 (2004) 397-414
34. Regunathan S., and Reis D.J. Imidazoline receptors and their endogenous ligands. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 511-544
35. Reis D.J., and Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann. N.Y. Acad. Sci. 881 (1999) 65-80
36. Reis D.J., and Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol. Sci. 21 (2000) 187-193
37. Rénéric J.P., Bouvard M., and Stinus L. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology 24 (2001) 379-390
38. Santos A.R.S., Gadotti V.M., Oliveira G.L., Tibola D., Paszcuka A.F., Neto A., Spindola H.M., Souza M.M., Rodrigues A.L.S., and Calixto J.B. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 48 (2005) 1021-1034
39. 1 imidazoline/α2-adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats. Pain 85 (2000) 161-167
40. Willner P. The validity of animal models of depression. Psychopharmacology 83 (1984) 1-16
41. Yesilyurt O., and Uzbay T. Agmatine potentiates the analgesic effect of morphine by an α2-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 25 (2001) 98-103
42. Zomkowski A.D.E., Hammes L., Lin J., Calixto J.B., Santos A.R.S., and Rodrigues A.L.S. Agmatine produces antidepressant-like effects in two models of depression in mice. NeuroReport 13 (2002) 387-391
43. Zomkowski A.D.E., Rosa A.O., Lin J., Santos A.R.S., Calixto J.B., and Rodrigues A.L.S. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res. 1023 (2004) 253-263
44. Zomkowski A.D.E., Santos A.R.S., and Rodrigues A.L.S. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci. Lett. 381 (2005) 279-283
45. Zuh H., Paul I.A., Stec D.E., and Piletz J.E. Non-adrenergic exploratory behaviour induced by moxonidine at mildly hypotensive doses. Brain Res. 964 (2003) 9-20